Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

WuXi Biologics to Discover mAbs for BioNTech for $20 Million Upfront

publication date: Jan 12, 2024

Shanghai WuXi Biologics signed a research service agreement with Germany’s BioNTech to discover investigational monoclonal antibodies for two undisclosed targets. WuXi Bio will receive $20 million upfront in exchange for exclusive rights to these mAbs, and it is eligible to receive payments for R&D along with milestones and tiered royalties. BioNTech, which developed one of the two original siRNA vaccines for COVID (and partnered it with Pfizer), is using its cash to expand into oncology therapies, with a goal of having ten candidates in registrational trials by the end of 2024. More details...

Stock Symbols: (HK: 2269) (NSDQ: BNTX)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital